BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+3.35%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$17.4B
AUM Growth
+$17.4B
(+0.42%)
Cap. Flow
-$234M
Cap. Flow
% of AUM
-1.35%
Top 10 Holdings %
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14
Top Buys
| 1 |
Roivant Sciences
ROIV
|
$28.6M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$20.8M |
| 3 |
AbCellera Biologics
ABCL
|
$19.8M |
| 4 |
Denali Therapeutics
DNLI
|
$17.3M |
| 5 |
Immunovant
IMVT
|
$16.3M |
Top Sells
| 1 |
argenx
ARGX
|
$63.4M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$55.9M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$48.1M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$28.7M |
| 5 |
AnaptysBio
ANAB
|
$12M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Fate Therapeutics
FATE
$115M
| – | – |
-1,671,717
| Closed | -$7.96M |
|
102
FibroGen
FGEN
$48.4M
| – | – |
-9,523
| Closed | -$643K |
|
103
MacroGenics
MGNX
$121M
| – | – |
-892,579
| Closed | -$4.78M |
|
|
MREO
104
Mereo BioPharma
MREO
$275M
| – | – |
-3,554,979
| Closed | -$4.69M |
|
105
Nkarta
NKTX
$149M
| – | – |
-271,329
| Closed | -$594K |
|
106
Spyre Therapeutics
SYRE
$1.02B
| – | – |
-136,404
| Closed | -$1.54M |
|
107
Vera Therapeutics
VERA
$1.47B
| – | – |
-146,464
| Closed | -$2.35M |
|
108
Verastem
VSTM
$585M
| – | – |
-1,336,485
| Closed | -$9.94M |
|
|
VINC
109
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| – | – |
-11,279
| Closed | -$293K |
|
|
IMGN
110
DELISTED
Immunogen Inc
IMGN
| – | – |
-1,520,097
| Closed | -$28.7M |
|
|
ARAV
111
DELISTED
Aravive, Inc. Common Stock
ARAV
| – | – |
-3,261,224
| Closed | -$4.11M |
|
|
KDNY
112
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-1,455,202
| Closed | -$55.9M |
|
|
DICE
113
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| – | – |
-1,035,786
| Closed | -$48.1M |
|